RxDoctor Payments Data

Cynthia Aranow

Rheumatology · Manhasset, NYNPI 1710023536

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $49,036 of the $59,161 with a category attached, or 82.9%. 11 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.4% of the total. 2025 is the largest year on record at $19,795, more than ten times the $1,217 reported in 2019. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,161in general payments, 2019–2025

Across 67 payments — averaging $882.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$16K
  • GSK$12K
  • Astrazeneca UK Limited$10K
  • UCB SA$6K
  • AstraZeneca$4K
  • Biogen$3K
  • plus $8K from 5 others
$5,255,308in research payments, 2019–2025

Across 226 payments — averaging $23,254 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$4.4M
  • Boehringer Ingelheim$224K
  • Amgen$222K
  • Pfizer$140K
  • UCB SA$140K
  • Janssen Research & Development, LLC$117K
  • plus $5K from 3 others

What the payments were for

  • Consulting fees$49,03683%
  • Speaking & faculty fees$6331%
  • Grants$3,7516%
  • Travel & lodging$4,2037%
  • Food & beverage$1,5373%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,161 in reported general payments places this provider in the 90th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
BenlystaBelimumab11$47,110
Mycophenolate Mofetil28$4,007
Hydroxychloroquine Sulfate71$2,724
Azathioprine12$363
Prednisone21$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$11,822$47,11011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 541 rheumatology providers in New York.

Other rheumatology in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →